Zev Lagstein, MD
Cardiovascular Disease · Las Vegas, NVNPI 1104873876
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 136 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,561 and has fallen 68.2% since, to $497 in 2025.
Across 136 payments — averaging $50.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Abbott$834
- Boehringer Ingelheim$708
- E.r. Squibb & Sons, L.L.C.$643
- Johnson & Johnson$582
- Pfizer$575
- plus $2K from 12 others
What the payments were for
- Food & beverage$6,86699%
- Education$671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $1,548 |
| Abbott | 6 | $834 |
| Boehringer Ingelheim | 11 | $708 |
| E.r. Squibb & Sons, L.L.C. | 9 | $643 |
| Johnson & Johnson | 10 | $582 |
| Pfizer | 17 | $575 |
| Actelion Pharmaceuticals US, Inc. | 6 | $516 |
| Bayer | 8 | $332 |
| Novo Nordisk | 14 | $292 |
| Amarin Pharma, Inc. | 5 | $279 |
| Edwards Lifesciences | 2 | $172 |
| Novartis | 3 | $144 |
| Boston Scientific | 2 | $137 |
| Sanofi-aventis U.S. LLC | 4 | $76 |
| Philips North America LLC | 2 | $50 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| Cvrx, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$874
- JARDIANCE$583
- XARELTO$495
- UPTRAVI$453
- ELIQUIS$452
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$431
- OPSUMIT$341
- CAMZYOS$241
- Vascepa$238
- Kerendia$238
- AVEIR$170
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$142
- MitraClip$129
- WATCHMAN Access System$125
- LOKELMA$122
- Ozempic$113
- VYNDAQEL$109
- ENSITE$104
- ENTRESTO$101
How this compares
$6,933 in reported general payments places this provider in the 65th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 65 | $64,278 |
| FarxigaDapagliflozin Propanediol | 59 | $52,435 |
| XareltoRivaroxaban | 42 | $48,705 |
| OzempicSemaglutide | 32 | $39,750 |
| JardianceEmpagliflozin | 15 | $21,667 |
| Propafenone Hcl ErPropafenone Hcl | 11 | $2,387 |
| Hydralazine Hcl | 148 | $2,203 |
| Levothyroxine Sodium | 81 | $2,175 |
| Nebivolol Hcl | 21 | $1,817 |
| Losartan Potassium | 155 | $1,708 |
| Amlodipine Besylate | 217 | $1,656 |
| Fenofibrate | 34 | $1,443 |
| SynthroidLevothyroxine Sodium | 25 | $1,403 |
| Atorvastatin Calcium | 168 | $1,368 |
| Gabapentin | 39 | $1,256 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $575 | $64,27865 claims |
| AstraZenecaFarxiga | $1,548 | $52,43559 claims |
| Johnson & JohnsonXarelto | $582 | $48,70542 claims |
| Novo NordiskOzempic | $292 | $39,75032 claims |
| Boehringer IngelheimJardiance | $708 | $21,66715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Las Vegas
- Arjun GururajLas Vegas$399K
- Branavan UmakanthanLas Vegas$109K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Chowdhury AhsanLas Vegas$41K
- Sanjay MalhotraLas Vegas$41K
- William ReshLas Vegas$39K
- Ali NamaziLas Vegas$38K
- Herbert Cordero YordanLas Vegas$38K
- Alfred DanielianLas Vegas$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.